Skip to main content

Accelr8 Reports Declining Revenues, Increased Losses in Q2 of FY2004

NEW YORK, March 16 (GenomeWeb News) - Accelr8 Technology today reported growing losses and shrinking revenues for the second quarter of its fiscal year 2004.


The company booked $153,000 in revenues for the quarter, which ended Jan. 31, down from $202,000 during the same period a year ago.


R&D expenses stayed essentially flat at $138,000, compared to $136,000 during the same quarter last year.


Losses amounted to $372,000, or $.04 per share, up from $281,000, or $.03 per share, during the year-ago period.


The company did not state its cash or cash equivalents.


Accelr8, of Denver, also said that it expects Schott Nexterion to become the exclusive outsource manufacturer and marketer of its OptArray products this fall.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.